Publications (18) Publications in which a researcher has participated

filter_list Internal Medicine

2025

  1. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

    The Lancet, Vol. 405, Núm. 10474, pp. 216-232

  2. Phosphatidylserine as a tumor target for CAR-T cell therapy

    Journal for ImmunoTherapy of Cancer, Vol. 13, Núm. 2

  3. Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis using reconstructed RCT survival data

    JHEP Reports, Vol. 7, Núm. 3

2024

  1. Comprehensive in silico CpG methylation analysis in hepatocellular carcinoma identifies tissue- and tumor-type specific marks disconnected from gene expression

    Journal of Physiology and Biochemistry, Vol. 80, Núm. 4, pp. 865-879

  2. Correction to: Explainable artificial intelligence prediction-based model in laparoscopic liver surgery for segments 7 and 8: an international multicenter study (Surgical Endoscopy, (2024), 38, 5, (2411-2422), 10.1007/s00464-024-10681-6)

    Surgical Endoscopy

  3. Correction: Cost-effectiveness of robotic vs laparoscopic distal pancreatectomy. Results from the national prospective trial ROBOCOSTES (Surgical Endoscopy, (2024), 38, 11, (6270-6281), 10.1007/s00464-024-11109-x)

    Surgical Endoscopy

  4. Current Role of CT Pulmonary Angiography in Pulmonary Embolism: A State-of-the-Art Review

    Journal of Imaging, Vol. 10, Núm. 12

  5. Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies

    CardioVascular and Interventional Radiology, Vol. 47, Núm. 3, pp. 310-324

  6. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

    Annals of Oncology, Vol. 35, Núm. 5, pp. 448-457

  7. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

    Gut, Vol. 74, Núm. 1, pp. 116-127

  8. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU

    Revista espanola de enfermedades digestivas, Vol. 116, Núm. 2, pp. 83-113

  9. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432

  10. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 4, pp. 381-391

  11. PET/CT FAPI: Procedure and evidence review in oncology

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 43, Núm. 2, pp. 130-140

  12. Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolization

    JHEP Reports, Vol. 6, Núm. 4

  13. Repeated pancreatic resection for pancreatic metastases from renal cell Carcinoma: A Spanish multicenter study (PANMEKID)

    Surgical Oncology, Vol. 52

  14. Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysis

    British Journal of Surgery, Vol. 111, Núm. 2

  15. Textbook outcome in patients with biliary duct injury during cholecystectomy

    Journal of Gastrointestinal Surgery, Vol. 28, Núm. 5, pp. 725-730